成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. 誘導(dǎo)疾病模型產(chǎn)品 Cell Cycle/DNA Damage
  3. 免疫與炎癥疾病模型 泌尿系統(tǒng)疾病模型 生殖系統(tǒng)疾病模型 DNA Alkylator/Crosslinker
  4. 膀胱炎模型 心肌炎模型
  5. Cyclophosphamide

Cyclophosphamide  (Synonyms: 環(huán)磷酰胺)

目錄號: HY-17420 純度: 99.90%
COA 產(chǎn)品使用指南 技術(shù)支持

Cyclophosphamide 是一種合成的 DNA Alkylator，在化學(xué)上與氮芥類有關(guān)，具有抗腫瘤及免疫抑制活性。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Cyclophosphamide Chemical Structure

Cyclophosphamide Chemical Structure

CAS No. : 50-18-0

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
100 mg ￥720
In-stock
200 mg ￥1100
In-stock
500 mg ￥2000
In-stock
1 g ￥3400
In-stock
5 g   詢價(jià)  
10 g   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Cyclophosphamide:

MCE 顧客使用本產(chǎn)品發(fā)表的 28 篇科研文獻(xiàn)

  • 生物活性

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic activity, a immunosuppressant.

IC50 & Target

DNA Alkylator[1]
細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
COS-1 IC50
125.43 μM
Compound: CYC-PHO
Cytotoxicity against african green monkey COS1 cells after 24 hrs by MTT assay
Cytotoxicity against african green monkey COS1 cells after 24 hrs by MTT assay
[PMID: 23202484]
DU-145 IC50
52.5 μM
Compound: CPA
Cytotoxicity against human DU145 cells by MTT assay
Cytotoxicity against human DU145 cells by MTT assay
[PMID: 21689869]
HCT-15 IC50
74.32 μM
Compound: CYC-PHO
Cytotoxicity against human HCT15 cells after 24 hrs by MTT assay
Cytotoxicity against human HCT15 cells after 24 hrs by MTT assay
[PMID: 23202484]
HCT-15 IC50
76.32 μM
Compound: CYC-PHO
Growth inhibition of human HCT15 cells after 24 hrs by MTT assay
Growth inhibition of human HCT15 cells after 24 hrs by MTT assay
[PMID: 28011220]
HEK-293T IC50
> 100 μM
Compound: CYC-PHO
Growth inhibition of HEK293T cells after 24 hrs by MTT assay
Growth inhibition of HEK293T cells after 24 hrs by MTT assay
[PMID: 28011220]
HEK-293T IC50
> 100 μM
Compound: CP
Cytotoxicity against human HEK293T cells by MTT assay
Cytotoxicity against human HEK293T cells by MTT assay
[PMID: 20850303]
HeLa IC50
71.4 μM
Compound: CPA
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
[PMID: 21689869]
HEp-2 IC50
> 100 μM
Compound: CP
Cytotoxicity against human Hep2 cells by MTT assay
Cytotoxicity against human Hep2 cells by MTT assay
[PMID: 20850303]
HepG2 IC50
0.24 μM
Compound: CP
Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay
Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay
10.1007/s00044-011-9737-7
HepG2 IC50
52.3 μM
Compound: CYC-PHO
Growth inhibition of human HepG2 cells after 24 hrs by MTT assay
Growth inhibition of human HepG2 cells after 24 hrs by MTT assay
[PMID: 28011220]
HepG2 IC50
55.3 μM
Compound: CYC-PHO
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
[PMID: 23202484]
HL-60 IC50
8.79 μM
Compound: CP
Cytotoxicity against human HL60 cells by MTT assay
Cytotoxicity against human HL60 cells by MTT assay
[PMID: 20850303]
K562 IC50
0.15 μM
Compound: CP
Cytotoxicity against Homo sapiens (human) K562 cells after 48 hr by MTT assay
Cytotoxicity against Homo sapiens (human) K562 cells after 48 hr by MTT assay
10.1007/s00044-011-9737-7
K562 IC50
0.153 μM
Compound: CP
Antiproliferative activity against Homo sapiens (human) K562 cells after 48 hr by MTT assay
Antiproliferative activity against Homo sapiens (human) K562 cells after 48 hr by MTT assay
10.1007/s00044-010-9466-3
L1210 IC50
> 300 μM
Compound: Cyclophosphamide
Concentration required to reduce the viability of L1210 cells by 50% after 1-h incubation at 37 degrees C
Concentration required to reduce the viability of L1210 cells by 50% after 1-h incubation at 37 degrees C
[PMID: 1992116]
MCF7 IC50
0.16 μM
Compound: Cyclophosphamide
Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by trypan blue assay
Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by trypan blue assay
10.1007/s00044-009-9222-8
MDA-MB-231 IC50
0.09 μM
Compound: CP
Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells after 48 hr by MTT assay
Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells after 48 hr by MTT assay
10.1007/s00044-011-9737-7
MDA-MB-231 IC50
195.5 μM
Compound: Cyclophosphamide
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
[PMID: 33139111]
NCI-H522 IC50
67.9 μM
Compound: CYC-PHO
Cytotoxicity against human NCI-H522 cells after 24 hrs by MTT assay
Cytotoxicity against human NCI-H522 cells after 24 hrs by MTT assay
[PMID: 23202484]
NCI-H522 IC50
69.9 μM
Compound: CYC-PHO
Growth inhibition of human NCI-H522 cells after 24 hrs by MTT assay
Growth inhibition of human NCI-H522 cells after 24 hrs by MTT assay
[PMID: 28011220]
PA-1 IC50
64.12 μM
Compound: CYC-PHO
Growth inhibition of human PA1 cells after 24 hrs by MTT assay
Growth inhibition of human PA1 cells after 24 hrs by MTT assay
[PMID: 28011220]
PA-1 IC50
64.12 μM
Compound: CYC-PHO
Cytotoxicity against human PA1 cells after 24 hrs by MTT assay
Cytotoxicity against human PA1 cells after 24 hrs by MTT assay
[PMID: 23202484]
T47D IC50
69 μM
Compound: CYC-PHO
Growth inhibition of human T47D cells after 24 hrs by MTT assay
Growth inhibition of human T47D cells after 24 hrs by MTT assay
[PMID: 28011220]
T47D IC50
70.1 μM
Compound: CYC-PHO
Cytotoxicity against human T47D cells after 24 hrs by MTT assay
Cytotoxicity against human T47D cells after 24 hrs by MTT assay
[PMID: 23202484]
體外研究
(In Vitro)

Cyclophosphamide 誘導(dǎo)外膜起泡，導(dǎo)致 DNA 片段化，如游離 3'-OH DNA 末端的 TUNEL 染色所示，并誘導(dǎo) 9L/P450 細(xì)胞中半胱天冬酶 3 和半胱天冬酶 7 底物 PARP 的裂解。Bcl-2 表達(dá)完全阻斷用活化 Cyclophosphamide 處理的細(xì)胞中啟動子半胱天冬酶以及效應(yīng)子半胱天冬酶 3 的激活。Bcl-2 抑制細(xì)胞毒性作用，但不抑制活化 Cyclophosphamide 的細(xì)胞生長抑制作用[1]。
Cyclophosphamide 可逆地抑制 AChE，IC50 為 511 μM[2]。
四氯化碳不影響 Cyclophosphamide 或4-羥基 Cyclophosphamide 對培養(yǎng)細(xì)胞的直接細(xì)胞毒性[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
體內(nèi)研究
(In Vivo)

Cyclophosphamide (CP) 可用于構(gòu)建卵巢早衰模型和骨髓抑制、免疫抑制模型，可通過肝酶 (細(xì)胞色素 P450) 酶促轉(zhuǎn)化為細(xì)胞毒性 4-羥基環(huán)磷酰胺 (4OHCP)。Cyclophosphamide 在動力學(xué)方面具有巨大的種間和種內(nèi)差異。狗微粒體催化 CP 生物活化的效率比人微粒體高 55 倍，比貓微粒體高 2.8 倍，比小鼠微粒體高 1.2 倍。

1. 卵巢早衰模型[6]
致病原理
環(huán)磷酰胺 (Cy) 通過引起原始卵泡激活而誘發(fā)卵巢功能不全 (POI)。
具體造模方法：
小鼠：Balb/C • 雌性 • 5 周齡
給藥方式：150 mg/kg • 腹腔注射 • 單劑量
Note
造模成功指標(biāo)
卵巢初級卵泡數(shù)量減少。
相關(guān)產(chǎn)品： /
拮抗產(chǎn)品： HY-P74413

2. 骨髓抑制和免疫抑制[7]
致病原理
環(huán)磷酰胺通過干擾骨髓 (BM) 細(xì)胞的增殖和分化來誘導(dǎo)骨髓抑制。
具體造模方法：
小鼠：Swiss • 雄性 • 6 周齡
給藥方式：150 mg/kg • 腹腔注射 • 單劑量[7].
Note
引起骨髓組織結(jié)構(gòu)的重要變化，降低骨髓/紅細(xì)胞比率，并減少血液白細(xì)胞數(shù)量。
造模成功指標(biāo)
引起骨髓組織結(jié)構(gòu)的重要變化，降低骨髓/紅細(xì)胞比率，并減少血液白細(xì)胞數(shù)量。
相關(guān)產(chǎn)品： /
拮抗產(chǎn)品： HY-N0045

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Six to eight-week old female C3H/HeN mice bearing SW1 tumors[4]
Dosage: 2 mg/mouse
Administration: Injected i.p.; 2mg/mouse in 0.1 mL PBS; 4 days
Result: Increased the percentage of cells that stained for CD3, CD4 or CD8 in both spleens and tumors.
Clinical Trial
分子量

261.09

Formula

C7H15Cl2N2O2P
CAS 號
性狀

固體

顏色

White to off-white

中文名稱

環(huán)磷酰胺
運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.
儲存方式

4°C, protect from light

*該產(chǎn)品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)用現(xiàn)配，即刻使用。

溶解性數(shù)據(jù)
細(xì)胞實(shí)驗(yàn)： 

DMSO 中的溶解度 : 100 mg/mL (383.01 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

H2O 中的溶解度 : 33.33 mg/mL (127.66 mM; 超聲助溶)

配制儲備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 3.8301 mL 19.1506 mL 38.3011 mL
5 mM 0.7660 mL 3.8301 mL 7.6602 mL
查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液；該產(chǎn)品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)用現(xiàn)配，即刻使用。

* 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

  • 摩爾計(jì)算器

  • 稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動物實(shí)驗(yàn)：

請根據(jù)您的 實(shí)驗(yàn)動物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

  • 方案 一

    請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (9.58 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (9.58 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

    2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

  • 方案 一

    請依序添加每種溶劑： PBS

    Solubility: 25 mg/mL (95.75 mM); 澄清溶液; 超聲助溶 (<60°C)

動物溶解方案計(jì)算器
請輸入動物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動物的平均體重

g

每只動物的給藥體積

μL

動物數(shù)量

只
由于實(shí)驗(yàn)過程有損耗，建議您多配一只動物的量
計(jì)算結(jié)果
工作液所需濃度 : mg/mL
該產(chǎn)品水溶性佳，請具體參考實(shí)測 水 / PBS / Saline 中的溶解度數(shù)據(jù)。
您所需的儲備液濃度超過該產(chǎn)品的實(shí)測溶解度，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
純度 & 產(chǎn)品資料

純度: 99.90%

參考文獻(xiàn)

完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液；該產(chǎn)品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)用現(xiàn)配，即刻使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 3.8301 mL 19.1506 mL 38.3011 mL 95.7528 mL
5 mM 0.7660 mL 3.8301 mL 7.6602 mL 19.1506 mL
10 mM 0.3830 mL 1.9151 mL 3.8301 mL 9.5753 mL
15 mM 0.2553 mL 1.2767 mL 2.5534 mL 6.3835 mL
20 mM 0.1915 mL 0.9575 mL 1.9151 mL 4.7876 mL
25 mM 0.1532 mL 0.7660 mL 1.5320 mL 3.8301 mL
30 mM 0.1277 mL 0.6384 mL 1.2767 mL 3.1918 mL
40 mM 0.0958 mL 0.4788 mL 0.9575 mL 2.3938 mL
50 mM 0.0766 mL 0.3830 mL 0.7660 mL 1.9151 mL
60 mM 0.0638 mL 0.3192 mL 0.6384 mL 1.5959 mL
80 mM 0.0479 mL 0.2394 mL 0.4788 mL 1.1969 mL
100 mM 0.0383 mL 0.1915 mL 0.3830 mL 0.9575 mL

* 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱：

  

* 需求量：

* 客戶姓名：

 

* Email：

* 電話：

 

* 公司或機(jī)構(gòu)名稱：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱：
Cyclophosphamide
目錄號：
HY-17420
需求量：